Benefits and Risks of Solitary Islet Transplantation for Type 1 Diabetes Using Steroid-Sparing Immunosuppression

Hirshberg, Boaz; Rother, Kristina I.; Digon, Benigno J.; Harlan, David M.

doi:10.2337/diacare.27.5.1250

Cited by 10 publications

(13 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Portal vein thrombosis in clinical islet transplantation is now judged to be relatively safe but there are still potentially life-threatening complications reported, mainly following IAT [13,28,29]. In our own experience, partial portal venous thrombosis occurred in 3.7% of our 268 procedures in 122 subjects (data not shown).…”

Section: Discussionmentioning

confidence: 78%

A comparison of islet autotransplantation with allotransplantation and factors elevating acute portal pressure in clinical islet transplantation

Kawahara

Kin

Shapiro

2011

J Hepato Biliary Pancreat

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 78%

A comparison of islet autotransplantation with allotransplantation and factors elevating acute portal pressure in clinical islet transplantation

Kawahara

Kin

Shapiro

2011

J Hepato Biliary Pancreat

View full text Add to dashboard Cite

show abstract

“…Allogeneic islet transplantation is procedure-based and clinician-led, reflecting the severity of its indication (severe hypoglycemic episodes in type 1 diabetes) and a consequent riskbenefit analysis that justifies immunosuppression [58]. These two are clear examples of the administration of cells that themselves have been shown not to be injurious in order to alleviate a severe indication.…”

Section: Mapping Cell Therapies To the Three Dimensionsmentioning

confidence: 99%

“…Dendreon's (Seattle, WA, http://www.dendreon.com) autologous dendritic cell therapy for prostate cancer is already on the market in the U.S., pointing to the advantages offered by an autologous cell therapy in the context of prostate cancer [57,58]. Allogeneic islet transplantation is procedure-based and clinician-led, reflecting the severity of its indication (severe hypoglycemic episodes in type 1 diabetes) and a consequent riskbenefit analysis that justifies immunosuppression [58]. These two are clear examples of the administration of cells that themselves have been shown not to be injurious in order to alleviate a severe indication.…”

Section: Mapping Cell Therapies To the Three Dimensionsmentioning

confidence: 99%

Concise Review: Cell Therapies: The Route to Widespread Adoption

Foley

Whitaker

2012

Stem Cells Translational Medicine

View full text Add to dashboard Cite

We identify three dimensions with which to classify heuristically the routes to widespread adoption of cellular therapies. The first dimension is based on the relative involvement of clinicians and companies in a particular cellular therapy. The second dimension is based on cell type and consequent scale of manufacture. The third dimension classifies the therapeutic intervention as a procedure or product and has perhaps received less attention. We suggest that for those cellular therapies that require therapeutic procedures, close collaboration between companies and clinicians will reduce the time to widespread adoption. For selected cellular therapies we make predictions of the likely time to widespread adoption. STEM CELLS TRANSLATIONAL MEDICINE 2012;1:438 -447

show abstract

“…Moreover, there are insufficient available organs for transplantation. Although pancreas islet transplantation is of low invasiveness, simplistic, safe, and has a wide spectrum of potential implementation sites (portal vein, gastric submucosa) [3,4], the biggest disadvantage is significant loss of islets immediately after the transplantation procedure -as a chronic inflammatory response and absence of extracellular matrix. The solution in the treatment of the T1D disease seems to be a bio-printed bionic pancreas, which overcomes many of the limitations presented above.…”

Section: Introductionmentioning

confidence: 99%

Use of 3D bioprinting in biomedical engineering for clinical application

Karzyński¹,

Kosowska²,

Ambrożkiewicz³

et al. 2018

View full text Add to dashboard Cite

Tissue engineering is a widely developing scientific field, which combines technological solutions with the biology of the living organism. Regenerative medicine that uses tools of tissue engineering offers alternative means of therapy enhancing damaged tissues or organs. One of the development directions of contemporary chemical engineering is the scientific description of novel technologies that will enable production of porous structures -with high utility for biomedical engineering. 3D printing is one of the most popular methods used to produce scaffolds for cell culture. Nowadays a research team, in which authors are currently working, is dealing with the problem of manufacturing 3D constructs that play the role of artificial organ, obtained via 3D bioprinting. In the current article we present the possibilities and limitations of 3D bioprinting method in the context of possible application of manufactured structures as fully functional organs. StreszczenieInżynieria tkankowa stanowi dynamicznie rozwijającą się dziedzinę nauki łączącą rozwiązania techniki z biologią żywe-go organizmu. Medycyna regeneracyjna, korzystając z narzędzi inżynierii tkankowej, oferuje alternatywne podejście do terapii wspomagających odbudowę zniszczonych tkanek czy narządów. Jednym z kierunków rozwoju współczesnej inży-nierii chemicznej jest opracowanie nowoczesnych technologii umożliwiających wywarzanie struktur porowatych o wysokiej użyteczności w inżynierii biomedycznej. Wśród najbardziej popularnych metod wykorzystywanych do wytwarzania rusztowań do hodowli komórek jest technika druku 3D. Obecnie zespół badawczy, w którym pracują autorzy, opracowuje technikę wytwarzania za pomocą biodruku 3D konstruktów spełniających funkcję sztucznych narządów. W artykule przedstawiono zestawienie możliwości i ograniczeń omawianej metody biodruku 3D w kontekście możliwości zastosowania wytworzonych struktur jako funkcjonalnych sztucznych organów.

show abstract

Benefits and Risks of Solitary Islet Transplantation for Type 1 Diabetes Using Steroid-Sparing Immunosuppression

Cited by 10 publications

References 5 publications

A comparison of islet autotransplantation with allotransplantation and factors elevating acute portal pressure in clinical islet transplantation

A comparison of islet autotransplantation with allotransplantation and factors elevating acute portal pressure in clinical islet transplantation

Concise Review: Cell Therapies: The Route to Widespread Adoption

Use of 3D bioprinting in biomedical engineering for clinical application

Contact Info

Product

Resources

About